Diethyldithiocarbamate (DDC) is a major metabolite of disulfiram that is a potential drug for alcoholism treatment. In the present study, we attempted to explore the possible effect of DDC on non-alcoholic fatty liver disease (NAFLD) and related fibrosis in vivo.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive hepatic fat accumulation and defined by the presence of steatosis in >5% of hepatocytes. NAFLD includes two pathological conditions with different prognoses: nonalcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH); the latter causes an elevated risk for cirrhosis and hepatocellular carcinoma (European Association for the Study of the Liver (EASL), et al. 2016). The prevalence of NAFLD is increasing annually worldwide and has become a major cause of end-stage liver diseases and liver transplantation in western countries (Mittal et al., 2016; Vernon et al., 2011; Younossi et al., 2018) . It is also increasingly recognized as an important aetiology of chronic liver diseases in China (Fan and Farrell, 2009) .
Lifestyle modification consisting of diet, exercise, and weight loss has been advocated to treat patients with NAFLD (EASL, et al. 2016) . However, no data are currently available on their long-term effects on the natural history of NAFLD. Drug therapy should be indicated for progressive NASH but also for early-stage NASH with increased risk of the development of fibrosis (Adams et al., 2005) or active NASH with high necroinflammatory activity (Sanyal et al., 2015) . Up to now, no drugs have been approved for NASH by the regulatory agencies. Therefore, it is of immediate importance to identify effective therapeutic agents for NAFLD.
Disulfiram (DSF) is a drug that has been used for over six decades as a treatment for alcohol dependence (Diehl et al., 2010) , with well-established pharmacokinetics, safety and tolerance at the US Food and Drug Administrationrecommended dosage (Cvek, 2012) . In the body, DSF is metabolized to dithiocarb [diethyldithiocarbamate (DDTC or DDC)], and sodium DDC was used to treat high-risk breast cancer in a clinical trial (Dufour et al., 1993) . A recent nationwide epidemiological study revealed that patients who continuously used DSF have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis (Skrott et al., 2017) . DDC or DSF is widely used for inhibiting cytochrome P450 2E1 (CYP2E1) in human studies because of its known selectivity and relative non-toxicity (Pratt-Hyatt et al., 2010) . It has been reported that low doses of DDC protect against liver injury induced by many hepatotoxic agents via its inhibition of drug-metabolizing enzymes and antioxidant effects in rats (Stott et al., 1997) . Additionally, DDC is a well-known NF-κB inhibitor. DDC interferes with the NF-κB pathway by inhibiting the nuclear translocation of NF-κB (Matsuno et al., 2012) . We previously demonstrated that DDC up-regulates MMP-1 in hepatic stellate cells via the ERK1/2 and Akt signalling pathways in vitro (Liu et al., 2013; Liu et al., 2016) . However, the possible effect of DDC on NAFLD and related fibrosis in vivo is still unknown.
In this study, the rats used were fed a methionine cholinedeficient (MCD) diet that induced NAFL with severe steatosis. The mice used were also fed a MCD diet, which induced NASH with severe hepatocyte ballooning, inflammation and fibrosis formation in these animals. We then investigated the effect of DDC on steatosis, hepatocyte ballooning, inflammation and fibrosis respectively.
Methods

Experimental animals
Animal experiments were approved by the Laboratory Animal Centre, affiliated with Beijing Friendship Hospital [SYXK (Jing) 2012-0023], and were performed in accordance with institutional and national legal guidelines for animal protection. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010) .
Eight-week-old male C57BL/6 mice and 6-week-old male Sprague Dawley (SD) rats were obtained from Beijing HFK Bio-Technology, Beijing, China. All animals were housed in a 12 h light-dark cycle in a temperature-controlled room and had free access to food and water. All animals were randomized into different groups. The investigator was not blind to the experimental groups.
NASH mouse model
The MCD diet is one of the best described dietary models for NAFL and NASH (Van Herck et al., 2017) . C57BL/6 mice fed a MCD diet showed severe hepatic necroinflammation with a lesser degree of steatosis (Kirsch et al., 2003) . Thus, in this study, we used mice fed the MCD diet to investigate the effect of DDC on hepatocyte ballooning, inflammation and fibrosis. The MCD and the methionine and choline-sufficient (MCS; normal control) diets were purchased from MP Biomedicals (Solon, OH, USA). Eight-week-old male C57BL/6 mice were randomly assigned to three independent groups (group size: n = 8): MCS group, MCD group and MCD + DDC group. The MCS group were kept on MCS control diet for 8-weeks. The MCD group were kept on the MCD diet and treated with vehicle (1 × PBS) via daily gavage for 8 weeks. MCD + DDC group were kept on the MCD diet and treated with 450 mg·kg À1 DDC (D3506, CAS number: 20624-25-3, Sigma-Aldrich, St. Louis, MO, USA) via daily gavage for 8 weeks by a technician blinded to the study design. At the end of the experiment, the mice were killed, and liver tissues and serum were obtained for analysis.
NAFL rat model
The liver injury and model of NASH induced by the MCD diet depends on the rodent species (Kirsch et al., 2003) . Rats develop extensive steatosis when fed a MCD diet, while inflammation and necrosis are minor features, and fibrosis is absent. Therefore, in this study, we used rats fed a MCD diet to investigate the effect of DDC on steatosis. Six-week-old male SD rats were randomly assigned to three independent groups (group size: n = 10): MCS group, MCD group and MCD + DDC group. The MCS group were kept on the MCS control diet for 6 weeks. The MCD group were kept on the MCD diet and treated with vehicle (1 × PBS) via daily gavage for 6 weeks. The MCD + DDC group were kept on the MCD diet and treated with 312 mg·kg À1 DDC via daily gavage for 6 weeks by a technician blinded to the study design. At the end of the experiment, the rats were killed, and liver tissues and serum were obtained for analysis.
Serum analyses
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (CHO), HDL and LDL were determined by the Central Laboratory of Deyi Diagnostics (Beijing, China) according to standardized and regularly validated criteria.
Histochemistry and immunohistochemical analyses
Formalin-fixed liver samples were deparaffinized and stained with haematoxylin and eosin for determination of the NAFLD activity score including steatosis, ballooning and inflammation (Kleiner et al., 2005) . Collagen was stained using Sirius Red, and hepatic lipid was stained with Oil red O. Sirius red-stained sections were observed under both visible light and polarized light. Immunohistochemistry (IHC) was performed on formalin-fixed sections. After rehydration of deparaffinized sections, antigens were retrieved at 95°C using citrate buffer (pH 6.0) for 30 min, followed by incubation overnight at 4°C using the following primary antibodies: mouse monoclonal antibody KP1against CD68 (Abcam Cat# ab955, RRID:AB_307338) at 1:500 dilution, rabbit polyclonal antibody against inducible NOS (iNOS) (Abcam Cat# ab15323, RRID:AB_301857) at 1:100 dilution, rabbit polyclonal antibody against CD206 (Abcam Cat# ab64693, RRID:AB_1523910) at 1:1000 dilution and rabbit polyclonal antibody ACTA2 against α-smooth muscle actin (α-sma, Abcam Cat# ab5694, RRID:AB_2223021) at 1:500 dilution. Rabbit polyclonal antibody against BCl2-associated X protein (Bax) (Cat# GB11007) at 1:500 dilution and rabbit polyclonal antibody against cleaved caspase-3 (Cat# GB11009) at 1:500 dilution were purchased from Servicebio (Beijing, China). The primary antibodies were detected with corresponding HRP-labelled secondary antibodies (Thermo Fisher Scientific, Waltham, MA, USA). The experiments were performed by a technician blinded to the experimental groups. Tissues were visualized in a Nikon Eclipse Ni-U microscope (Nikon Corporation, Tokyo, Japan) with the appropriate filters. Representative images were taken with a Nikon DS-Ri2 microscope camera (Nikon). Quantitative image analysis of staining was performed using Nikon NIS-Elements Software.
Real-time RT-PCR
The total RNA was isolated from liver tissues using TRIzol® reagent (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions. The total RNA yields were quantified, and the equivalent amounts of total RNA (2 μg) were reverse-transcribed into single-stranded cDNA. Equal amounts of cDNA were subjected to PCR in the presence of SYBR green dye using the ABI Power SYBR Green PCR Master Mix kit on an ABI Prism 7500 Sequence Detector (Applied Biosystems, Foster City, CA, USA). PCR without a template was used as the negative control; β-actin mRNA was used as an internal control. The primers were shown in Supporting Information Tables S1 and S2 . PCR was performed with 45 cycles of 15 s at 95°C and 60 s at 60°C after a 2 min initial denaturation at 95°C. Each sample was normalized according to the difference in the critical thresholds (CT) between the target gene and β-actin and relative to the control. The amount of the target was calculated as 2 ÀΔΔCT . All experiments were performed independently three times, and the averages were used for the comparisons.
Western blot analysis
Samples of liver tissue (100 mg) were immediately solubilized in lysis buffer at 4°C for 30 min. Following microcentrifugation at 14 000× g for 5 min, the supernatants were transferred into a new tube, and the sample protein concentrations were determined using the Pierce Protein assay kit (Pierce, Rockford, IL, USA). The protein mixtures were loaded into each well and separated on 12% SDS-PAGE. Following a 2 h run, the proteins were transferred onto nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were blocked and subsequently incubated with rabbit polyclonal antibody against CYP2E1 (Abcam Cat# ab28146, RRID:AB_2089985) at 1:2000 dilution and mouse monoclonal antibody against β-actin (Sigma-Aldrich Cat# A5441, RRID:AB_476744) at 1:5000 dilution at 4°C overnight. After extensive washing, the membranes were incubated with the secondary antibody for 60 min followed by extensive washes. Specific antibody-antigen complexes were detected with ECL Western blot detection kits (Pierce, Rockford, IL, USA). All experiments were performed independently three times, and the averages were used for the comparisons. Protein expression was quantified via densitometric analyses of the immunoblots using the Quantity One software.
Double immunofluorescence
For immunofluorescence, formalin-fixed liver samples were deparaffinized and rehydrated. Liver sections were immersed in EDTA antigen retrieval buffer (pH 8.0) and maintained at a sub-boiling temperature for 15 min. After being washed three times with PBS (pH 7.4), the sections were blocked using 3% BSA for 30 min. The sections were incubated overnight at 4°C with rabbit monoclonal antibody EP1628Y against keratin 8 (K8) (Abcam Cat# ab53280, RRID: AB_869901) at 1:200 dilution and mouse monoclonal antibody P4D1 against ubiquitin (Santa Cruz Biotechnology Cat# sc-8017, RRID:AB_628423) at 1:200 dilution. After being washed three times with PBS, the primary antibodies were detected with corresponding Alexa Fluor-conjugated anti-IgG, and the nuclei were counterstained with DAPI. The experiments were performed by a technician blinded to the experimental groups.
Microarray analyses of mouse liver samples
Total RNA was isolated from individual liver samples (n = 2 liver samples for MCS group, n = 3 liver samples for MCD group and n = 3 liver samples for MCD + DDC group) using TRIzol® reagent and were reverse-transcribed into cDNA. cDNA gene expression analysis was performed on a mouse Oligo Microarray (Mouse OneArray Plus, Phalanx Biotech Group, Hsinchu, Taiwan) by BGI-Beijing according to the manufacturer's instructions. The experiments were performed by a technician blinded to the experimental groups. The data were processed and analysed using Agilent 0.1 XDR software (Agilent Technologies, Santa Clara, CA, USA). Differentially expressed genes were mapped into biological processes or pathways using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes.
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . All statistical analyses were performed using SPSS software, version 16.0. Data are expressed as mean ± SEM. One-way ANOVA with post hoc Dunnett's multiple comparisons test was used for multiple groups. Post hoc tests were run only if F achieved P < 0.05, and there was no significant variance inhomogeneity. P < 0.05 was regarded as statistically significant.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
DDC attenuates hepatic steatosis in NAFL rats
We first examined the impact of DDC on MCD diet-induced NAFL in rats. Compared to rats on MCS diet, rats on MCD diet for 6 weeks showed a pronounced hepatic steatosis. Treatment with DDC significantly attenuated MCD-induced hepatic steatosis ( Figure 1A, B) . As shown in Figure 1C , MCD diet suppressed serum levels of CHO and HDL in rats, while DDC treatment could rescue the decrease of CHO and HDL. We then examined whether DDC regulated genes involved in fatty acid synthesis in rats. Similar to previous studies (Rinella et al., 2008) , MCD diet significantly down-regulated the expression of genes involved in fatty acid synthesis such as fatty acid synthase (Fas) and stearoyl-CoA desaturase (Scd1). DDC treatment significantly up-regulated the expression of Fas ( Figure 1D ).
DDC modulates parameters related to lipid metabolism in NASH mice
Although DDC-treated mice did not show significant histological changes of hepatic steatosis, parameters related to fatty acid metabolism in serum and the expression of fatty acid synthesis-related genes in the liver changed significantly. As shown in Supporting Information Figure  S1A -C, MCD diet suppressed serum levels of CHO, HDL and LDL in mice, while DDC treatment rescued the decrease of these parameters. MCD diet significantly down-regulated the expression of genes involved in fatty acid synthesis including Fas, sterol regulatory elementbinding protein-1 (Srebp-1) and Scd1. Compared with MCD diet group, DDC treatment significantly up-regulated the expression of Fas, while DDC group did not show significant changes in the expression of Srebp-1 and Scd1 (Supporting Information Figure S1D-F) .
DDC reduces oxidative stress, endoplasmic reticulum (ER) stress and apoptosis in the liver of NASH mice
We next investigated the effect of DDC on MCD dietinduced oxidative stress and ER stress in the liver. As shown in Figure 2A , MCD diet induced the up-regulation of CYP2E1 in mice liver, and DDC treatment significantly inhibited the increase of CYP2E1. As shown in Figure 2B -C, MCD diet induced the expression of ER stress-related gene, C/EBP homologous protein (CHOP) and activating transcription factor 4 (ATF4), while DDC treatment significantly blocked the increase in CHOP and ATF4 in mice. These data indicate that DDC treatment could reduce the oxidative stress and ER stress induced by the MCD diet.
As shown in Figure 2D , the MCD diet induced the expression of pro-apoptotic protein Bax and the activation of its downstream target caspase-3 in the liver of mice. DDC treatment prevented the activation of Bax, which in turn resulted in decreased activation of caspase-3. These findings indicate that DDC inhibited the apoptosis induced by MCD diet.
DDC attenuates MCD diet-induced hepatic ballooning and Mallory-Denk body (MDB) formation in NASH mice
We then examined the impact of DDC on hepatic injury, including hepatic ballooning and MDB formation in mice liver. Compared to mice on MCS diet, mice on MCD diet for 8 weeks showed a severe hepatic ballooning. As shown in Figure 3A , there were many ballooned hepatocytes, which lost the cell shape and contained delicate strands of residual cytoplasmic material in MCD diet group. Treatment with DDC significantly attenuated MCD-induced hepatic ballooning, and the score of ballooning significantly decreased (Supporting Information Figure S2A ). The hepatocytes showed macrovesicular steatosis, where a single large fat droplet completely displaces the normal cytoplasm in mice treated with DDC ( Figure 3A) . As shown in Supporting Information Figure S2B -C, compared to mice on MCS diet, mice on MCD diet for 8 weeks showed high levels of serum ALT and AST, while DDC treatment suppressed the increase of ALT and AST. These data indicated that DDC ameliorated liver injury induced by MCD diet.
MDB formation in hepatocytes has been assessed by immunofluorescence staining for K8 and ubiquitin. As shown in Figure 3B , there was a significant increase in MDB numbers in MCD diet mice, and DDC treatment significantly reduced the number of MDBs. There was also an increase in K8 mRNA levels in MCD diet mice, and DDC treatment blocked the increase ( Figure 3C ). In addition, compared to mice on MCS diet, mice on MCD diet for 8 weeks induced the expression of CD73, which contributes to experimental MDB induction and is highly regulated in MDB associated liver injury in mice. DDC treatment inhibited the expression of CD73 ( Figure 3D ).
Figure 1
Treatment with DDC improves hepatic steatosis in rats fed a MCD diet for 6 weeks. Male SD rats were fed either MCD or MCS diets for 6 weeks. The MCD group were treated either with vehicle (1 × PBS) or 312 mg·kg Figure 4A-B) . Furthermore, the inflammation-related genes (TNF-α, CCR2 and CCR5) increased in the MCD mice and were all normalized by DDC treatment (Figure 4C-E MCD diet, and DDC inhibited these increases ( Figure 4F Figure S3A-D) . In addition, the suppression of CD68 + iNOS + M1 macrophages was more pronounced than CD68 + CD206 + M2 macrophages in the liver after DDC treatment. In line with the data of IHC and immunofluorescence, the expression of CD206 and iNOS increased in MCD mice, and iNOS was suppressed by DDC treatment (Supporting Information Figure S3E-F) . Taken together, DDC treatment mitigated the infiltration of macrophages and other myeloid cells and then inhibited the hepatic inflammation.
DDC suppresses MCD diet-induced liver fibrosis in NASH mice
Since DDC treatment significantly attenuated MCD dietinduced hepatic injury and inflammation, we next evaluated the effect of DDC on the development of hepatic fibrosis as a consequence of chronic liver injury. The changes of liver fibrosis were assessed by quantitative morphometric analyses for Sirius Red staining and α-sma immunostaining of liver sections. Mice on MCD diet developed hepatic fibrosis with collagen deposition around the centrilobular vein with some central-central and central-portal bridges in MCD diet-fed mice, and DDC treatment significantly attenuated MCD diet-induced collagen deposition ( Figure 5A-B) . Equally, morphometry for α-sma protein demonstrated a reduction of activated hepatic stellate cells (HSC) and myofibroblasts in MCD mice with DDC treatment (Figure 5C-D) . These results uniformly showed that DDC significantly attenuated MCD diet-induced hepatic fibrosis.
In agreement with the histological findings, the elevated expression of collagen 1α1 and collagen 1α2 in MCD-fed mice was ameliorated by treatment with DDC ( Figure 5E-F) . Furthermore, as shown in Supporting Information Figure  S4 , mRNA expression of TGF-β1 increased in MCD dietfed mice and was significantly suppressed by treatment with DDC.
DDC modulates lipid metabolism and oxidation-reduction process in NASH mice
To reveal the possible mechanisms of the protective effect of DDC on NAFLD, mice liver tissues from different groups were harvested, and the gene expression profile was analysed by microarray analysis (GSE113843). The top 296 differentially expressed genes were found to be highly associated with the protective effect of DDC on NAFLD, and the heat maps were shown in Figure 6A . Function enrichment analysis based on biological process identified the top 10 enriched GO terms (MCD + DDC group vs. MCD group) that were strongly affected by DDC treatment ( Figure 6B ). Among these biological processes, oxidation-reduction process, lipid metabolic process and fatty acid metabolic process were strongly affected by DDC treatment. The representative differentially expressed genes in oxidation-reduction and lipid metabolic processes were shown in Figure 7A -B. Pathway enrichment analysis identified the top 10 enriched pathways (MCD + DDC group vs. MCD group) that were strongly affected by DDC treatment ( Figure 6C ). Among these pathways, metabolic pathways, oxidative phosphorylation, NAFLD and PPAR signalling pathway were strongly affected by DDC treatment. The differentially expressed genes in NAFLD and PPAR signalling pathway were shown in Figure 7C -D. These data indicated that DDC might modulate MCD diet-induced disorder of lipid metabolism and oxidative stress, which could lead to hepatic injury, inflammation and subsequent fibrosis (Figure 8 ).
Discussions
As an old alcohol-abuse drug, DSF and its active metabolite DDC have also been identified as a tumour suppressor (Cvek, 2012; Dufour et al., 1993; Skrott et al., 2017) . Meanwhile, DDC is a NF-κB inhibitor and has been widely used for inhibition of CYP2E1 (Pratt-Hyatt et al., 2010; Matsuno et al., 2012) . However, whether DDC has a role in NAFLD and related fibrosis has not been explored. In the present study, our data showed that DDC treatment significantly suppressed MCD diet-induced steatosis in rats and oxidative stress, ER stress, hepatocyte ballooning, hepatic inflammation and subsequent liver fibrosis in mice.
NAFLD can be categorized histologically into NAFL and NASH. NAFL is defined as the presence of ≥5% hepatic steatosis without evidence of hepatocellular injury in the form of hepatocyte ballooning. NASH is defined as the presence of ≥5% hepatic steatosis and inflammation with hepatocyte injury (e.g. ballooning), with or without fibrosis (Chalasani et al., 2018) . MCD diet is one of the best described dietary models for NAFL and NASH, and species of rodent influence liver injury in MCD nutritional model of NASH (Kirsch et al., 2003) . Rats developed extensive steatosis when fed with MCD diet, while inflammation and necrosis were minor features, and fibrosis was absent. In contrast, C57BL/6 mice-fed MCD diet showed severe hepatic necroinflammation and perisinusoidal fibrosis with a lesser degree of steatosis (Kirsch et al., 2003) . In this study, we used rats fed with MCD diet to establish NAFL animal model and mice fed with MCD diet to establish NASH animal model.
In this study, we first investigated the possible effect of DDC on MCD diet-induced hepatic steatosis in rats. Our data showed that treatment with DDC significantly attenuated MCD diet-induced hepatic steatosis in rats. In agreement with previous studies (Rinella et al., 2008) , MCD diet-induced hypocholesterolaemia and decrease of HDL, while DDC treatment rescued hypocholesterolaemia and the decrease of HDL. In addition, DDC treatment could also correct the abnormal expression of fatty acid synthesis-related gene Fas in MCD diet-induced NAFL rats. These data indicated that the regulation of fatty acid synthesis by DDC might contribute to the suppression of MCD diet-induced hepatic steatosis.
We next investigated the possible effect of DDC on MCD diet-induced hepatic steatosis in mice. DDC treatment rescued hypocholesterolaemia and the abnormal of HDL and Fas in NASH mice. However, we did not observe significant changes of steatosis in histology, since C57BL/6 mice-fed MCD diet for 8 weeks only showed severe hepatic necroinflammation and perisinusoidal fibrosis rather than steatosis in histology. Schwartz et al. (2013) have investigated the effect of DSF (Synonym: tetraethylthiuram disulfide) on NASH mice. In their model, significant steatosis and inflammation but no fibrosis were observed in mice liver, and they have not observed significant changes of hepatic steatosis in DSF-treated mice. In their study, 20-week-old mice were used to establish NASH model induced by MCD diet for 6 weeks.
The histology difference between this study and our study might be due to the age of mice and how long the mice were treated with MCD diet.
Excess lipid accumulation in the liver will result in oxidative stress and ER stress, which play important roles in the development and progression of NAFLD (Machado and Diehl, 2016) . CYP2E1 is the major microsomal sources of oxidative stress in NAFLD (Robertson et al., 2001) . MCD diet-induced steatohepatitis is associated with up-regulated hepatocyte microsomal CYP2E1 activity and increased hepatic lipid peroxidation (Weltman et al., 1996) . Here, we showed that treatment with DDC significantly suppressed the increase of CYP2E1 in NASH mice. The unfolded protein response induced by hepatic lipid accumulation aggravates ER stress (Malhi and Kaufman, 2011) , and persistent ER stress leads to hepatocyte injury, apoptosis and fibrosis (Gentile et al., 2011) . Our data showed that MCD diet induced the expression of ER stress-related gene, ATF4 and CHOP in mice liver, while DDC treatment blocked the increase. These data indicated that DDC treatment attenuated the oxidative stress and ER stress induced by MCD diet. Prolonged cellular stresses can cause serious damage, leading to apoptosis (Ashraf and Sheikh, 2015) . Our data showed that MCD diet induced the expression of pro-apoptotic protein Bax and the activation of its downstream target caspase-3 in mice liver. DDC treatment inhibited the activation of Bax and caspase-3. Hepatocyte injury is also a defining lesion for NASH. Histologically, hepatocyte injury is indicated by hepatocyte ballooning that is characterized by an enlarged hyperchromatic nucleus and a foamy, pale cytoplasm (Brunt, 2011; Yeh and Brunt, 2014) . In this study, treatment with DDC attenuated MCD induced hepatic ballooning. The formation of MDBs is one of the other histological features of hepatocyte injury in NASH (Zatloukal et al., 2007) . MCD diet induced a significant increase in MDB numbers, while DDC treatment significantly reduced the number of MDBs. The abnormal expression of K8 is associated with the formation of MDB (Singla et al., 2012) . We found that MCD diet induced an increase in K8 mRNA, and DDC treatment blocked the increase. It has been demonstrated that CD73 contributes to experimental MDB induction and is highly regulated in MDB-associated liver injury in mice (Snider et al., 2013) . In this study, mice on MCD diet for 8 weeks induced the expression of CD73, while DDC treatment inhibited the expression of CD73. Hepatocyte injury will in turn trigger inflammatory and fibrogenic responses (Machado and Diehl, 2016) . Histologically, inflammation in NASH is manifested by infiltration of inflammatory cells including macrophages, monocytes, neutrophils, and lymphocytes (Harmon et al., 2011) . Proinflammatory cytokines such as TNF-α are secreted by injured hepatocytes and lead to increased macrophage infiltration (Harmon et al., 2011) . In agreement with Schwartz's study (Schwartz et al., 2013) , mice on a MCD diet showed a marked inflammatory cell infiltration in the liver, while DDC significantly attenuated hepatic inflammation. In addition, the inflammation-related genes (TNF-α, CCR2 and CCR5) increased in the MCD mice and were all normalized by DDC treatment. In Schwartz's study (Schwartz et al., 2013) , DSF also reduced the expression of TNF-α induced by the MCD diet. Imbalanced M1/M2 macrophages have emerged as a central mechanism underlying steatohepatitis. In NASH, macrophages are activated by various stimulants and shift to the pro-inflammatory M1 phenotype (Smith, 2013) . Our data showed that both CD68 + iNOS + M1 macrophages and CD68 + CD206 + M2 macrophages significantly increased in the liver of mice on MCD diet. DDC significantly attenuated MCD-induced infiltration of M1 and M2 macrophages. Furthermore, the suppression of M1 macrophages was more pronounced than M2 macrophages in the liver after DDC treatment. Taken together, data presented here showed that DDC treatment mitigated MCD diet-induced hepatocyte injury and induced secretion of pro-inflammatory cytokines and subsequent infiltration of inflammatory cells. The mechanisms involved in the progression of steatosis to NASH are complex and not completely understood (Than and Newsome, 2015) . The current view on the mechanisms underlying the development of NASH favours a model, in which steatosis and then steatohepatitis, induced by free fatty acid overload, insulin, oxidative stress, ER stress, hepatocyte lipoapoptosis, immune infiltration with activation of inflammatory cells and subsequent activation of HSC and myofibroblasts (Machado and Diehl, 2016) . In this study, our data showed that DDC treatment attenuated hepatic steatosis, cell stress, hepatocyte ballooning and inflammation. In addition, DDC treatment significantly suppressed the expression of fibrogenesis-related genes, the activation of HSC and myofibroblasts and subsequent collagen deposition in the liver of MCD-induced NASH mice. Microarray analyses showed that DDC strongly affected oxidative stress and lipid metabolism-related biological processes and pathways, including oxidation-reduction process, lipid metabolic process, fatty acid metabolic process, metabolic pathways, oxidative phosphorylation, NAFLD and PPAR signalling pathway. These data suggested that the modulation of lipid metabolism and oxidative stress by DDC might be involved in the prevention of MCD dietinduced NAFLD.
However, the present study still has some limitations. Firstly, a MCD diet-induced steatohepatitis model does not develop the typical metabolic abnormalities observed in human NASH, such as obesity, peripheral insulin resistance and hyperglycaemia. Further studies based on an animal model more closely resembling human NASH may be helpful to evaluate the applicability of DDC. Secondly, DDC was administered to the rats for all 6 weeks and the mice for all 8 weeks (early treatment group), and a later treatment schedule should be tried in the future. Thirdly, ATF4 and K8
Figure 8
Possible mechanisms of DDC-mediated amelioration of MCD diet-induced NAFLD.
mRNA levels showed a reduction in the MCD + DDC group compared to the MCS group. Whether this reduction is a side effect of the doses selected needs to be investigated in the future study. In addition, the detailed mechanism of DDC modulation on NAFLD and related fibrosis need to be elucidated in a future study.
In conclusion, the results presented here demonstrate that DDC attenuates MCD diet-induced steatosis in NAFL rats and hepatocyte ballooning, inflammation and fibrosis in NASH mice. Treatment with DDC may have therapeutic potential for NAFLD and related fibrosis. mean ± SEM. n = 8 mice per group. One-way ANOVA followed by Dunnett's post hoc test for multiple comparisons. *P < 0.05. Figure S4 Treatment with DDC suppresses the expression of TGF-β in livers of mice fed MCD diet for 8 weeks. Male C57BL/6 mice were fed either MCD or MCSdiets for 8 weeks. MCD group were treated either with vehicle (1×PBS) or 450 mg/kg DDC via daily gavage for all 8 weeks. The transcript levels of TGF-β in the liver of mice. Data are expressed as mean ± SEM. n = 8 mice per group. One-way ANOVA followed by Dunnett's post hoc test for multiple comparisons. *P < 0.05. Diethyldithiocarbamate alleviates NAFLD
